BridgeMD
New treatment option for Heart Transplant
Official title Randomized Trial of SGLT2i in Heart Transplant Recipients
ClinicalTrials.gov ID: NCT06625073
What this study is testing
What is Empagliflozin?
Empagliflozin is an investigational medicine, given as an once-daily, being studied as a potential treatment for heart transplant.
Also referred to as Jardiance.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- Heart transplant (HTx) is an established therapy for advanced heart disease that restores quality of life and improves survival. However, due to preexisting comorbidities combined with the immunosuppressive therapies required after transplantation, HTx recipients remain at high risk for kidney, cardiovascular (CV), and metabolic disease.
- Phase 4: studies an already-approved treatment
- You might receive a placebo (an inactive treatment) instead of the study drug, decided by chance.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- Age 18 years or older
- Heart transplant recipient, 3 months after transplant
You likely can't join if
- eGFR \<20 mL/min/1.73m2
- Type 1 diabetes mellitus
- HbA1C \>10%
- Baseline UACR \<30 mg/g in patients without T2D
- Known allergy or intolerance to SGLT2i
- Active uncontrolled infection
See the full eligibility criteria
- Age 18 years or older
- Heart transplant recipient, 3 months after transplant
- eGFR \<20 mL/min/1.73m2
- Type 1 diabetes mellitus
- HbA1C \>10%
- Baseline UACR \<30 mg/g in patients without T2D
- Known allergy or intolerance to SGLT2i
- Active uncontrolled infection
- Multiorgan transplant
- SGLT2i treatment in the last 30 days
- Pregnancy, breast-feeding or woman of child-bearing age not on birth control
The study team makes the final eligibility decision.
Where it's taking place
- Palo Alto, California, United States
- Nashville, Tennessee, United States
- Houston, Texas, United States
- Salt Lake City, Utah, United States
- Richmond, Virginia, United States
- Madison, Wisconsin, United States
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Palo Alto, California, United States; Nashville, Tennessee, United States; Houston, Texas, United States; Salt Lake City, Utah, United States; Richmond, Virginia, United States; Madison, Wisconsin, United States. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.